GEN Exclusives

More »

GEN News Highlights

More »
Dec 13, 2011

Poll Voters Believe Geron Will Find a Partner for hESC Therapeutic Programs

  • Geron will find a partner for its human embryonic stem cell (hESC) therapeutic programs, a more than two-to-one majority of voters on GEN's poll agreed. With 63.1% saying yes, 31.5% believe the firm will not find a partner and 5.4% were undecided. Geron, a pioneer in stem cell research founded in 1990, announced on November 14 that it was halting its stem cell therapeutic programs and is seeking partners for these assets. At the time, Geron had been developing differentiated hESCs, with its lead product in Phase I for spinal cord injury. Advanced Cell Technology (ACT) remains the only company left with ongoing clinical trials involving hESCs.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?